BACE1 and Cognitive impairment: The first study analyzed BACE1 CSF concentrations and activity in a pooled cohort of cogntively healthy control (HC) individuals, clinically diagnosed patients with AD dementia (ADD), and individuals with mild cognitive impairment (MCI) [9].